LOTTE BIOLOGICS plans to operate a bio campus in Songdo, Incheon with a capacity of 360,000 liters by 2030.
Each plant will be capable of producing 120,000 liters of Drug Substance, and the addition of a small-scale bioreactor facility of 2,000 liters to accommodate clinical needs is currently under consideration.

Additionally, the campus will be capable of handling the "Fill & Finish" process, aiming to provide a one-stop service for the production of pharmaceutical products.

The Syracuse Bio Campus possesses the capacity for 40,000 liters of Drug Substance manufacturing as well as storage and quality control.

The campus is fully GMP operational with clinical and commercial capabilities.
The campus has received more than 62 approvals from global regulatory bodies including FDA, EMA, PMDA, and MFDS.

LOTTE BIOLOGICS has established a sales office within the Cambridge Innovation Center (CIC) in Boston, USA, to expand its communication channels with potential global customers.

Boston’s Cambridge Innovation Center (CIC) is a hub for innovation and entrepreneurship, serving as an ecosystem where diverse startups and world-renowned companies collaborate and grow.
Specializing in the bio and life sciences industry, the CIC provides an optimal space for a diverse range of companies to seamlessly conduct research and development as well as business expansion.

LOTTE BIOLOGICS looks forward to collaborations in the North American market and other global regions from the Boston biotech hub, long recognized as a strategic base for entering the global market.
Through the various events and programs hosted by the CIC,
the company aims to engage with leaders in the pharmaceutical and biotech industry, further attracting new customers and nurturing a wide range of new business opportunities.